You are viewing a historical snapshot of United States (NYSE / Nasdaq). These figures are a preview to show what TradeTidings covers. Live, continuously updated United States sentiment and stock impact is a Pro feature.
Get live United States data with ProRegeneron Pharmaceuticals (REGN)
3 stories published on REGN since June 2026. See all coverage.
News sentiment trend
Counts of positive, neutral, and negative news items over the last 90 days. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Sentiment timeline
How news sentiment on Regeneron Pharmaceuticals (REGN) has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
Why this reading
The recent items weighing most on this reading, by direction and influence.
Regeneron Stock: Why Disappointing Trial Results Are Weighing on REGN
Direct news · Medium influence · Long term
Regeneron Stock: REGN Sued Over Claims It Hid Cancer Drug Trial Data
Direct news · Low influence · Long term
FDA Selects Eli Lilly and Regeneron for Manufacturing Facility Fast-Track Initiative
Direct news · Low influence · Long term
Direct news
The most recent stories naming REGN directly, across all of our coverage.
Regeneron Stock: REGN Sued Over Claims It Hid Cancer Drug Trial Data
Regeneron Stock: Why Disappointing Trial Results Are Weighing on REGN
FDA Selects Eli Lilly and Regeneron for Manufacturing Facility Fast-Track Initiative
Indirect drivers in the news
Macro, commodity, FX and regulatory forces that have moved REGN, with the stories behind each.
No indirect-driver news for REGN in our coverage yet.
Also monitored for REGN (no news in our coverage yet): FDA approvals & trial outcomes, Drug pricing / FDA / IRA.
See the full picture
Sign up free to track REGN, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track REGN for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.